Literature DB >> 18155525

Primary hyperoxaluria: clinical course, diagnosis, and treatment after kidney failure.

Dharmapaul L Raju1, Marcelo Cantarovich, Marie-Laure Brisson, Jean Tchervenkov, Mark L Lipman.   

Abstract

Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive metabolic disorder resulting in the overproduction of plasma oxalate. Although the enzymatic defect is in hepatocyte peroxisomes, uncontrolled levels of oxalate result in calcium oxalate deposition in multiple organs. Because the primary route of elimination of oxalate is renal excretion, high levels are found in urine, which results in supersaturation and crystal nucleation. Patients typically present with recurrent nephrolithiasis and nephrocalcinosis. If not diagnosed early, end-stage renal disease (ESRD) and systemic calcium oxalate deposition can occur. Once ESRD develops, intensive dialysis therapy is unable to keep pace with the high oxalate production, and the preferred therapeutic intervention is combined kidney-liver transplantation. Here, we report a young man with a history of recurrent nephrolithiasis who presented to us with ESRD and subsequently developed manifestations of systemic oxalosis. The diagnosis of PH1 must be considered in the differential diagnosis of patients presenting with ESRD with a history of recurrent nephrolithiasis. The diagnosis of PH1 is more challenging in patients with ESRD, for whom urinary oxalate levels are often normal or only modestly increased because of decreased glomerular filtration, and recurrent nephrolithiasis is no longer the dominant clinical feature.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18155525     DOI: 10.1053/j.ajkd.2007.08.027

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

1.  Association of Urinary Oxalate Excretion With the Risk of Chronic Kidney Disease Progression.

Authors:  Sushrut S Waikar; Anand Srivastava; Ragnar Palsson; Tariq Shafi; Chi-Yuan Hsu; Kumar Sharma; James P Lash; Jing Chen; Jiang He; John Lieske; Dawei Xie; Xiaoming Zhang; Harold I Feldman; Gary C Curhan
Journal:  JAMA Intern Med       Date:  2019-04-01       Impact factor: 21.873

2.  HPO2Vec+: Leveraging heterogeneous knowledge resources to enrich node embeddings for the Human Phenotype Ontology.

Authors:  Feichen Shen; Suyuan Peng; Yadan Fan; Andrew Wen; Sijia Liu; Yanshan Wang; Liwei Wang; Hongfang Liu
Journal:  J Biomed Inform       Date:  2019-06-27       Impact factor: 6.317

3.  Adult with primary hyperoxaluria type 1 regrets not receiving preemptive liver transplantation during childhood: report of a case.

Authors:  Tomohide Hori; Toshimi Kaido; Nobuyuki Tamaki; Yasuko Toshimitsu; Kohei Ogawa; Shinji Uemoto
Journal:  Surg Today       Date:  2012-08-25       Impact factor: 2.549

4.  Liver transplantation for primary hyperoxaluria type 1: a single-center experience during two decades in Japan.

Authors:  Tomohide Hori; Hiroto Egawa; Toshimi Kaido; Kohei Ogawa; Shinji Uemoto
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

5.  Dual Glycolate Oxidase/Lactate Dehydrogenase A Inhibitors for Primary Hyperoxaluria.

Authors:  Jinyue Ding; Rajesh Gumpena; Marc-Olivier Boily; Alexandre Caron; Oliver Chong; Jennifer H Cox; Valerie Dumais; Samuel Gaudreault; Aaron H Graff; Andrew King; John Knight; Renata Oballa; Jayakumar Surendradoss; Tim Tang; Joyce Wu; W Todd Lowther; David A Powell
Journal:  ACS Med Chem Lett       Date:  2021-05-20       Impact factor: 4.632

Review 6.  Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria.

Authors:  Guillaume Bollée; Pierre Cochat; Michel Daudon
Journal:  Can J Kidney Health Dis       Date:  2015-09-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.